Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>DLBCL R/R*** > Treatment > DE. M. Fc Modified Cytolytic CD19>

---

MAb Inj for IV Use+

DE. M. Fc Modified Cytolytic CD19>'s subsections
(*) CA Approval Date: 2021. 08.24.
(*) EU Approval Date: ?
(*) HK Approval Date: 2022. 12.28
(*) USA Approval Date: 2020. 07.31.
+Lenalidomide
Company
Company (CoMarketing USA)
Company (Marketing CA)
Company (Marketing HK)
Generic Name: Tafasitamab
Patent>USA Patent Numbers
RTM CA
RTM USA
RTM USA Web-Site

DE. M. Fc Modified Cytolytic CD19>'s products
This section has no products